Cash, Cash Equivalents, and Marketable Securities
Merck & Co. Cash, Cash Equivalents, and Marketable Securities decreased by 30.3% to $101.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 81.2%, from $536.00M to $101.00M. Over 5 years (FY 2020 to FY 2025), Cash, Cash Equivalents, and Marketable Securities shows an upward trend with a 2.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher levels indicate strong liquidity and financial health, while lower levels may signal a need for external financing.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term invest...
Peer comparison
A standard liquidity metric reported by virtually all public companies on the balance sheet.
cash_equivalents_marketable_securities_totalHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $88.00M | $89.00M | $86.00M | $454.00M | $412.00M | $76.00M | $569.00M | $760.00M | $821.00M | $247.00M | $337.00M | $117.00M | $127.00M | $81.00M | $536.00M | $690.00M | $707.00M | $145.00M | $101.00M |
| QoQ Change | — | +1.1% | -3.4% | +427.9% | -9.3% | -81.6% | +648.7% | +33.6% | +8.0% | -69.9% | +36.4% | -65.3% | +8.5% | -36.2% | +561.7% | +28.7% | +2.5% | -79.5% | -30.3% |
| YoY Change | — | — | — | — | +368.2% | -14.6% | +561.6% | +67.4% | +99.3% | +225.0% | -40.8% | -84.6% | -84.5% | -67.2% | +59.1% | +489.7% | +456.7% | +79.0% | -81.2% |
Cash, Cash Equivalents, and Marketable Securities at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s cash, cash equivalents, and marketable securities?
- Merck & Co. (MRK) reported cash, cash equivalents, and marketable securities of $101.00M in Q4 2025.
- How has Merck & Co.'s cash, cash equivalents, and marketable securities changed year-over-year?
- Merck & Co.'s cash, cash equivalents, and marketable securities decreased by 81.2% year-over-year, from $536.00M to $101.00M.
- What is the long-term trend for Merck & Co.'s cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Merck & Co.'s cash, cash equivalents, and marketable securities has grown at a 2.6% compound annual growth rate (CAGR), from $89.00M to $101.00M.
- What does cash, cash equivalents, and marketable securities mean?
- The total value of the company's cash and highly liquid short-term investments.